ArticleInternational archives of allergy and immunology2011
Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy.
Article in International archives of allergy and immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01716312 (A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study With an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients With Lupus), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study With an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients With Lupus (STOP LUPUS)
Who cites it
28 citing papers in PubMed, 59 citations in OpenAlex.
- Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2019Trial
- Relationship of IgE to basophil phenotypes in peanut-sensitized adults.The Journal of allergy and clinical immunology · 2014Trial
- Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.The Journal of allergy and clinical immunology · 2012Trial
- Neutralizing serum IgE upregulates CD88 and CRTH2 expression on basophils in patients with asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.Clinical reviews in allergy & immunology · 2022Review
- Serum CD203c+ Extracellular Vesicle Serves as a Novel Diagnostic and Prognostic Biomarker for Succinylated Gelatin Induced Perioperative Hypersensitive Reaction.Frontiers in immunology · 2021Article
- Basophil Activation Test: Old and New Applications in Allergy.Current allergy and asthma reports · 2018Review
- Road map for the clinical application of the basophil activation test in food allergy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2017Review
- Acute Myeloid Leukemia with Basophilic Differentiation Transformed from Myelodysplastic Syndrome.Case reports in hematology · 2017Article
- Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Biomarkers for the Phenotyping and Monitoring of Asthma in Children.Current treatment options in allergy · 2016Review
- Earth Mover's Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell Populations.PloS one · 2016Article
- Basophil activation test: food challenge in a test tube or specialist research tool?Clinical and translational allergy · 2016Review
- The relationship between total cellular content of CD203c and cell surface expression on human basophils.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015Article
- The Potential of Anti-IgE in Food Allergy Therapy.Current treatment options in allergy · 2014Article
- Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2014Article
- Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).The Journal of allergy and clinical immunology · 2014Article
- Oral immunotherapy for the treatment of food allergy.Human vaccines & immunotherapeutics · 2014Review
- Increased level of basophil CD203c expression predicts severe chronic urticaria.Journal of Korean medical science · 2014Article
- Spontaneous basophil responses in food-allergic children are transferable by plasma and are IgE-dependent.The Journal of allergy and clinical immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
rationaleBasophils contribute to anaphylaxis and allergies. We examined the utility of assessing basophil-associated surface antigens (CD11b/CD63/CD123/CD203c/CD294) in characterizing and monitoring subjects with nut allergy.
methodsWe used flow cytometry to analyze basophils at baseline (without any activation) and after ex vivo stimulation of whole blood by addition of nut or other allergens for 2, 10, and 30 min. We also evaluated whether basophil expression of CD11b/CD63/CD123/CD203c/CD294 was altered in subjects treated with anti-IgE monoclonal antibody (omalizumab) to reduce plasma levels of IgE.
resultsWe demonstrate that basophil CD203c levels are increased at baseline in subjects with nut allergy compared to healthy controls (13 subjects in each group, p < 0.0001). Furthermore, we confirm that significantly increased expression of CD203c occurs on subject basophils when stimulated with the allergen to which the subject is sensitive and can be detected rapidly (10 min of stimulation, n = 11, p < 0.0008). In 5 subjects with severe peanut allergy, basophil CD203c expression following stimulation with peanut allergen was significantly decreased (p < 0.05) after 4 and 8 weeks of omalizumab treatment but returned toward pretreatment levels after treatment cessation.
conclusionsSubjects with nut allergy show an increase of basophil CD203c levels at baseline and following rapid ex vivo stimulation with nut allergen. Both can be reduced by omalizumab therapy. These results highlight the potential of using basophil CD203c levels for baseline diagnosis and therapeutic monitoring in subjects with nut allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.